In a high-dose melphalan setting, palifermin compared with placebo had no effect on oral mucositis or related patient's burden

Bone Marrow Transplantation

Volumn 48, Issue 7, 2013, Pages 966-971

  Blijlevens, N ^a   De Chateau M ^b   Krivan, G ^c   Rabitsch, W ^d   Szomor, A ^e   Pytlik, R ^f   Lissmats, A ^b   Johnsen, H E ^g   De Witte, T ^a   Einsele, H ^h   Ruutu, T ⁱ   Niederwieser, D ^j  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Clinical Development   (Sweden)

^c Szent Laszlo Hospital   (Hungary)

^d MEDICAL UNIVERSITY OF VIENNA   (Austria)

^e UNIVERSITY OF PÉCS   (Hungary)

^f CHARLES UNIVERSITY   (Czech Republic)

^g AALBORG UNIVERSITY HOSPITAL   (Denmark)

^h UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

ⁱ HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^j UNIVERSITY OF LEIPZIG   (Germany)

more..

Author keywords

efficacy; multiple myeloma; Oral mucositis; palifermin; quality of life; stem cell transplantation

Indexed keywords

MELPHALAN; PALIFERMIN; PLACEBO;

ADULT; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BACTEREMIA; CLINICAL ASSESSMENT; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG ERUPTION; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; ERYTHEMA; FEBRILE NEUTROPENIA; FEMALE; HERPES SIMPLEX; HUMAN; MAJOR CLINICAL STUDY; MALE; MOUTH CAVITY; MOUTH INFECTION; MULTICENTER STUDY; MULTIPLE MYELOMA; MYCOSIS; ORAL MUCOSITIS; OUTCOME ASSESSMENT; PERIPHERAL EDEMA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEPSIS; TREATMENT DURATION;

ADOLESCENT; ADULT; AGED; AUTOGRAFTS; FEMALE; FIBROBLAST GROWTH FACTOR 7; FOLLOW-UP STUDIES; HUMANS; MALE; MELPHALAN; MIDDLE AGED; MULTIPLE MYELOMA; MYELOABLATIVE AGONISTS; STEM CELL TRANSPLANTATION; STOMATITIS; TRANSPLANTATION CONDITIONING;

EID: 84880212893     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2012.257     Document Type: Article

References (21)

1. Spielberger R, Stiff P, Bensinger W, Gentile T, Weisdorf D, Kewalramani T et al. Palifermin for oral mucositis after intensive therapy for hematologic cancers. N Engl J Med 2004; 351: 2590-2598.
2. Blijlevens N, Schwenkglenks M, Bacon P, D'Addio A, Einsele H, Maertens J et al. Prospective oral mucositis audit: oral mucositis in patients receiving high-dose melphalan or BEAM conditioning chemotherapy-European Blood and Marrow Transplantation Mucositis Advisory Group. J Clin Oncol 2008; 26: 1519-1525.
3. Stiff PJ, Erder H, Bensinger WI, Emmanouilides C, Gentile T, Isitt J et al. Reliability and validity of a patient self-administered daily questionnaire to assess impact of oral mucositis (OM) on pain and daily functioning in patients undergoing autologous hematopoietic stem cell transplantation (HSCT). Bone Marrow Transplant 2006; 37: 393-401.
4. Hochberg Y. A sharper Bonferroni procedure for multiple tests of significance. Biometrika 1988; 75(4): 800-802.
5. Lehman EL. Nonparametrics. Holden-Day: San Francisco, 1975, pp 145.
6. Blazar BR, Weisdorf DJ, Defor T, Goldman A, Braun T, Silver S et al. Phase 1/2 randomized, placebo-control trial of palifermin to prevent graft-vs-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (HSCT). Blood 2006; 108: 3216-3222.
7. Spielberger R, Stiff P, Emmanouilides C. Efficacy of recombinant human keratinocyte growth factor (rHuKGF) in reducing mucositis in patients with hematologic malignancies undergoing autologous peripheral blood progenitor cell transplantation (auto-PBPCT) after radiation-based conditioning: results of a phase trial (abstract no.25). Proc Am Soc Clin Oncol 2001; 20(Pt 1): 7a.
8. Farrell CL, Bready JV, Rex KL, Chen JN, DiPalma CR, Whitcomb KL et al. Keratinocyte growth factor protects mice from chemotherapy and radiation-induced gastrointestinal injury and mortality. Cancer Res 1998; 58: 933-939.
9. Werner S, Smola H, Liao X, Longaker MT, Krieg T, Hofschneider PH et al. The function of KGF in morphogenesis of epithelium and reepithelialization of wounds. Science 1994; 266: 819-822.
10. Sonis ST. The pathobiology of mucositis. Nat Rev Cancer 2004; 4: 277-284.
11. Potten CS, Booth D, Cragg NJ, Tudor GL, O'Shea JA, Booth C et al. Cell kinetic studies in the murine ventral tongue epithelium: mucositis induced by radiation and its protection by pretreatment with keratinocyte growth factor (KGF). Cell Prolif 2002; 35(Suppl 1): 32-47.
12. Zia-Amirhosseini P, Salfi M, Leese P, Yates W, Danilenko DM, Ring B et al. Pharmacokinetics, pharmacodynamics, and safety assessment of palifermin (rHuKGF) in healthy volunteers. Clin Pharmacol Ther 2006; 79: 558-569.
13. Vadhan-Raj S, Trent J, Patel S, Zhou X, Johnson MM, Araujo D et al. Single-dose palifermin prevents severe oral mucositis during multicycle chemotherapy in patients with cancer: a randomized trial. Ann Intern Med 2010; 153: 358-367.
14. Lerman MA, Treister NS. Generalized white appearance of the oral mucosa. Hyperkeratosis secondary to palifermin. J Am Dent Assoc 2010; 141: 867-869.
15. Schroeder T, Zohren F, Saure C, Kobbe G, Palifermin HaasR. A recombinant human keratinocyte growth factor, triggers reactivation of anogenital human papillomavirus infection in a HIV-positive patient with diffuse large cell B-cell non- Hodgkin lymphoma. Bone Marrow Transplant 2009; 44: 823-824.
16. Kobbe G, Bruns I, Schroeder T, Czibere A, Warnecke J, Hieronimus N et al. A 3-day short course of palifermin before HDT reduces toxicity and need for supportive care after autologous blood stem-cell transplantation in patients with multiple myeloma. Ann Oncol 2010; 21: 1898-1904.
17. Elting LS, Shih YC, Stiff PJ, Bensinger W, Cantor SB, Cooksley C et al. Economic impact of palifermin on the costs of hospitalization for autologous hematopoietic stem-cell transplant: analysis of phase trial results. Biol Blood Marrow Transplant 2007; 13: 806-813.
18. Langner S, Staber P, Schub N, Gramatzki M, Grothe W, Behre G et al. Palifermin reduces incidence and severity of oral mucositis in allogeneic stem-cell transplant recipients. Bone Marrow Transplant 2008; 42: 275-279.
19. Goldberg JD, Zheng J, Castro-Malaspina H, Jakubowski AA, Heller G, van den Brink MR et al. Palifermin is efficacious in recipients of TBI-based but not chemotherapy- based allogeneic hematopoietic stem cell transplants. Bone Marrow Transplant 2012; 48: 99-104.
20. Peterson DE, Bensadoun RJ, Roila F. Management of oral and gastrointestinal mucositis: ESMO Clinical Practice Guidelines. Ann Oncol 2011; 22(Suppl 6): vi78-vi84.
21. Grazziutti ML, Dong L, Miceli MH, Krishna SG, Kiwan E, Syed N et al. Oral mucositis in myeloma patients undergoing melphalan-based autologous stem cell transplantation: incidence, risk factors and a severity predictive model. Bone Marrow Transplant 2006; 38: 501-506.